ATE524739T1 - Verfahren zur auswahl von behandlungsschemata und vorhersage von behandlungsresultaten bei krebspatienten - Google Patents
Verfahren zur auswahl von behandlungsschemata und vorhersage von behandlungsresultaten bei krebspatientenInfo
- Publication number
- ATE524739T1 ATE524739T1 AT03736436T AT03736436T ATE524739T1 AT E524739 T1 ATE524739 T1 AT E524739T1 AT 03736436 T AT03736436 T AT 03736436T AT 03736436 T AT03736436 T AT 03736436T AT E524739 T1 ATE524739 T1 AT E524739T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- adjuvant
- upa
- pai
- subject
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 7
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 abstract 5
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 abstract 5
- 239000002671 adjuvant Substances 0.000 abstract 3
- 238000002512 chemotherapy Methods 0.000 abstract 3
- 206010006187 Breast cancer Diseases 0.000 abstract 2
- 238000009260 adjuvant endocrine therapy Methods 0.000 abstract 2
- 238000001959 radiotherapy Methods 0.000 abstract 2
- 230000004083 survival effect Effects 0.000 abstract 2
- 238000011269 treatment regimen Methods 0.000 abstract 2
- 102000013566 Plasminogen Human genes 0.000 abstract 1
- 108010051456 Plasminogen Proteins 0.000 abstract 1
- 102000018779 Replication Protein C Human genes 0.000 abstract 1
- 108010027647 Replication Protein C Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35692802P | 2002-02-13 | 2002-02-13 | |
| US40231102P | 2002-08-09 | 2002-08-09 | |
| PCT/US2003/004538 WO2003082072A2 (en) | 2002-02-13 | 2003-02-13 | Methods for selecting treatment regimens and predicting outcomes in cancer patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE524739T1 true ATE524739T1 (de) | 2011-09-15 |
Family
ID=28678149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03736436T ATE524739T1 (de) | 2002-02-13 | 2003-02-13 | Verfahren zur auswahl von behandlungsschemata und vorhersage von behandlungsresultaten bei krebspatienten |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20060084056A1 (de) |
| EP (3) | EP1563302B1 (de) |
| AT (1) | ATE524739T1 (de) |
| AU (2) | AU2003237779B2 (de) |
| CA (1) | CA2476352A1 (de) |
| ES (1) | ES2373547T3 (de) |
| WO (1) | WO2003082072A2 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060210979A1 (en) * | 2003-01-13 | 2006-09-21 | Lily Yang | Methods of detecting gene expression in normal and cancerous cells |
| US8168568B1 (en) | 2003-03-10 | 2012-05-01 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Combinatorial therapy for protein signaling diseases |
| US20050244893A1 (en) * | 2004-04-16 | 2005-11-03 | Wyeth | Novel method for determination of plasminogen activator inhibitor |
| CN102680686A (zh) * | 2004-08-13 | 2012-09-19 | 千年药品公司 | 用于鉴定、评估、预防和治疗前列腺癌的基因、组合物、试剂盒和方法 |
| FR2886946B1 (fr) * | 2005-06-09 | 2007-08-10 | Biomerieux Sa | Procede pour le diagnoctic/pronostic du cancer du sein |
| US20070156453A1 (en) * | 2005-10-07 | 2007-07-05 | Brainlab Ag | Integrated treatment planning system |
| DK2117571T3 (en) | 2006-12-08 | 2017-05-08 | Monopar Therapeutics Inc | Urokinase-type plasminogen activator receptor epitope |
| WO2010073248A2 (en) * | 2008-12-24 | 2010-07-01 | Rosetta Genomics Ltd. | Gene expression signature for classification of tissue of origin of tumor samples |
| RU2352270C1 (ru) * | 2007-11-19 | 2009-04-20 | Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт "Росмедтехнологий" | Способ лечения рака прямой кишки |
| EP2093567A1 (de) * | 2008-02-21 | 2009-08-26 | Pangaea Biotech, S.A. | Brca1-mRNA-Expressionsebenen zur Vorhersage der Überlebensaussichten von mit neoadjuvanter Chemotherapie behandelten Brustkrebspatienten |
| US20100304373A1 (en) * | 2008-08-14 | 2010-12-02 | Ricciardi Robert P | Methods for Assessing the Susceptibility of a Human to Diminished Health and Wellness |
| US20110195848A1 (en) * | 2010-01-08 | 2011-08-11 | Roopra Avtar S | Gene expression and breast cancer |
| JP6002379B2 (ja) * | 2011-11-29 | 2016-10-05 | シスメックス株式会社 | 癌の再発リスクの判定方法及びその利用 |
| WO2013154767A1 (en) * | 2012-04-09 | 2013-10-17 | Yale University | Compositions and methods for diagnosing and treating neoplasia |
| US20140081659A1 (en) | 2012-09-17 | 2014-03-20 | Depuy Orthopaedics, Inc. | Systems and methods for surgical and interventional planning, support, post-operative follow-up, and functional recovery tracking |
| CA2893745A1 (en) * | 2012-12-04 | 2014-06-12 | Caris Mpi, Inc. | Molecular profiling for cancer |
| ES2663482T3 (es) * | 2013-08-01 | 2018-04-12 | Fundación Pública Andaluza Progreso Y Salud | Método para predecir la respuesta al tratamiento y prueba para el uso seguro de células madre mesenquimatosas en enfermedades inflamatorias |
| US20190147986A1 (en) * | 2016-05-17 | 2019-05-16 | Abraxis Bioscience, Llc | Methods for assessing neoadjuvant therapies |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JPH07500961A (ja) | 1990-10-01 | 1995-02-02 | ユニバーシティ オブ コネチカット | 細胞による選択的内在化を目的としたウイルス及び細胞の標的設定 |
| DE69231736T2 (de) | 1991-05-14 | 2001-10-25 | The Immune Response Corp., Carlsbad | Gerichtete abgabe von genen, die immunogene proteine kodieren |
| JPH06510278A (ja) | 1991-06-05 | 1994-11-17 | ユニバーシティ オブ コネチカット | 分泌タンパク質をコードする遺伝子の標的への配達 |
| WO1993014188A1 (en) | 1992-01-17 | 1993-07-22 | The Regents Of The University Of Michigan | Targeted virus |
| US5326856A (en) | 1992-04-09 | 1994-07-05 | Cytogen Corporation | Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding |
| DK85193D0 (da) * | 1993-07-16 | 1993-07-16 | Cancerforskningsfondet Af 1989 | Suppression of inhibitors |
| US5449761A (en) | 1993-09-28 | 1995-09-12 | Cytogen Corporation | Metal-binding targeted polypeptide constructs |
| US5635493A (en) | 1993-12-01 | 1997-06-03 | Marine Polymer Technologies, Inc. | Methods and compositions for poly-β-1-4-N-acetylglucosamine chemotherapeutics |
| DE69733462T2 (de) * | 1996-04-12 | 2006-03-23 | American National Red Cross | Mutierter plasminogen-aktivator-inhibitor typ 1 und seine verwendungen |
| US5816397A (en) | 1997-01-21 | 1998-10-06 | Ogio International, Inc. | Golf club carrying apparatus |
| AU2003213594A1 (en) * | 2002-03-01 | 2003-09-16 | Bayer Corporation | Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples |
-
2003
- 2003-02-13 US US10/504,287 patent/US20060084056A1/en not_active Abandoned
- 2003-02-13 EP EP03736436A patent/EP1563302B1/de not_active Expired - Lifetime
- 2003-02-13 AU AU2003237779A patent/AU2003237779B2/en not_active Ceased
- 2003-02-13 CA CA002476352A patent/CA2476352A1/en not_active Abandoned
- 2003-02-13 WO PCT/US2003/004538 patent/WO2003082072A2/en not_active Application Discontinuation
- 2003-02-13 EP EP10181640.3A patent/EP2360476B1/de not_active Expired - Lifetime
- 2003-02-13 ES ES03736436T patent/ES2373547T3/es not_active Expired - Lifetime
- 2003-02-13 AT AT03736436T patent/ATE524739T1/de not_active IP Right Cessation
- 2003-02-13 EP EP10181772.4A patent/EP2302385B1/de not_active Expired - Lifetime
-
2008
- 2008-07-29 AU AU2008203388A patent/AU2008203388A1/en not_active Abandoned
-
2018
- 2018-03-28 US US15/938,888 patent/US20180282822A1/en not_active Abandoned
-
2019
- 2019-01-17 US US16/250,042 patent/US20190233899A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2302385A1 (de) | 2011-03-30 |
| EP2360476B1 (de) | 2017-10-25 |
| US20180282822A1 (en) | 2018-10-04 |
| AU2008203388A1 (en) | 2008-08-21 |
| EP2360476A1 (de) | 2011-08-24 |
| EP1563302A4 (de) | 2007-12-12 |
| WO2003082072A2 (en) | 2003-10-09 |
| EP1563302A2 (de) | 2005-08-17 |
| AU2003237779A1 (en) | 2003-10-13 |
| US20060084056A1 (en) | 2006-04-20 |
| WO2003082072A3 (en) | 2005-06-16 |
| AU2003237779B2 (en) | 2008-06-26 |
| EP2302385B1 (de) | 2014-12-03 |
| US20190233899A1 (en) | 2019-08-01 |
| EP1563302B1 (de) | 2011-09-14 |
| CA2476352A1 (en) | 2003-10-09 |
| ES2373547T3 (es) | 2012-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE524739T1 (de) | Verfahren zur auswahl von behandlungsschemata und vorhersage von behandlungsresultaten bei krebspatienten | |
| Mendenhall et al. | Giant cell tumor of bone | |
| AU2003260966A8 (en) | Genes and polypeptides relating to human pancreatic cancers | |
| ATE423217T1 (de) | Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten | |
| ATE529535T1 (de) | Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe | |
| Langendijk et al. | Radiotherapy of squamous cell carcinoma of the nasal vestibule | |
| WO2004007770A3 (en) | Method for diagnosis of intestinal-type gastric tumors | |
| Murakami et al. | Increase of IL-12 following reconstruction for total en bloc spondylectomy using frozen autografts treated with liquid nitrogen | |
| MXPA05014220A (es) | Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos. | |
| Victorson et al. | Measuring quality of life in cancer survivors | |
| Wisniewski et al. | The effect of radiotherapy and hormone therapy on osteopontin concentrations in prostate cancer patients | |
| Chen et al. | Retrospective study of selective neck dissection versus radical neck dissection as salvage therapy for patients with recurrent nasopharyngeal squamous cell carcinoma | |
| Addeo et al. | Prognostic significance of residual lymphovascular invasion after resection of locally advanced and borderline resectable pancreatic adenocarcinomas treated by neoadjuvant chemotherapy | |
| WO2001004343A3 (en) | A method for determining the prognosis of cancer patients by measuring levels of bag expression | |
| Tupper et al. | Extent of Surgery and Survival of Osteosarcoma: A Retrospective Population-Based Study | |
| Woźniak et al. | The effect of combined therapy on activity of cathepsin D and alpha-1-antitrypsin in the blood serum of women with cervical cancer | |
| Crosetti et al. | Partial Laryngeal Surgery in 2023 | |
| Safin et al. | Combined treatment of giant cell bone tumor | |
| Liang et al. | Outcomes of MR-guided stereotactic body radiotherapy (SBRT) or yttrium-90 transarterial radioembolization for hepatocellular carcinoma treated at an urban liver transplant center | |
| Lim et al. | Defining the operative time threshold in patients undergoing minimally invasive right hepatectomy | |
| Afonin et al. | EFFICACY OF HYPOFRACTIONATED ADJUVANT RADIATION THERAPY IN PATIENTS WITH OPERABLE BREAST CANCER | |
| Taylor et al. | Dynamic optical contrast imaging as a novel modality to rapidly distinguish oral squamous cell carcinoma from surrounding normal tissue | |
| Slade et al. | Racial Differences in the Role of the PSA Bounce in Predicting Prostate Cancer Outcomes after Radiotherapy: Evidence from the Department of Veterans Affairs | |
| DE502004012140D1 (de) | Verfahren zur In-Vitro-Diagnose eines Glioms oder Astrozytoms und pharmazeutische Mischung zur Behandlung des Glioms, Astrozytoms oder eines Rezidivs davon | |
| Ball | MTE24. 02 Small Lung Tumours: High Risk Lesions and Contraindications to Stereotactic Ablative Body Radiotherapy (SABR) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |